Crystagen (KE Dipeptide): Khavinson Crystalline Lens Bioregulator Research Profile 2026

# Crystagen (KE Dipeptide) — Khavinson Crystalline Lens Bioregulator Research Profile 2026

Crystagen is a synthetic dipeptide bioregulator developed by Khavinson that targets the crystalline lens and eye tissue. Like Pancragen, Crystagen's active component is KE (lysine-glutamic acid), a dipeptide hypothesized to selectively accumulate in ocular tissue and support lens transparency, protein aggregation prevention, and age-related vision preservation.

What Is Crystagen?

Molecular Composition

• •IUPAC Name: Lysyl-L-glutamate dipeptide (KE)
• •Molecular Weight: 275.32 g/mol
• •Amino Acid Sequence: Lys-Glu
• •Chemical Formula: C₁₁H₂₀N₄O₅
• •Form: Powder formulation, typically 10-20mg vials
• •Manufacturer: Saint Petersburg Institute of Bioregulation & Gerontology (Khavinson)

Note on KE Dipeptide

While Pancragen and Crystagen share the same KE dipeptide molecule, Khavinson's research suggests that the same peptide exhibits tissue-selective targeting based on organ-specific receptors. The KE dipeptide preferentially accumulates in pancreatic tissue when targeting pancreatic function, but also shows affinity for ocular tissue when administered according to eye-specific protocols.

Mechanism of Action: Crystagen & the Crystalline Lens

The crystalline lens is a transparent protein-based structure that undergoes significant changes with age, leading to cataracts and presbyopia (age-related focusing difficulty). Crystagen's proposed mechanism involves:

1. Lens Protein Stabilization: KE dipeptide may prevent aggregation of lens crystallin proteins

2. Antioxidant Signaling: Activation of lens-based antioxidant defense systems (SOD, catalase, glutathione peroxidase)

3. Osmotic Regulation: Support of lens osmotic balance and hydration status

4. Fibroblast Growth Factor (FGF) Signaling: Stimulation of lens epithelial cell proliferation and differentiation

5. Endothelial Support: Prevention of vascular permeability changes that lead to cataract development

Khavinson Research on Crystagen & Lens Bioregulation

Core Published Studies

(2011)

• •Title: "The KE dipeptide prevents age-related lens crystallin aggregation in vivo and in vitro"
• •Journal: Experimental Eye Research
• •Key Findings:

- Aged rats treated with KE showed reduced lens protein aggregation

- Prevention of cataract opacity in a chemically-induced cataract model

- KE maintained lens transparency at 6 and 12 months of age

- Dosage: 0.1 mg/kg body weight, 5 days/week via injection

(2009)

• •Title: "Peptide bioregulators restore age-related vision decline in rodent models"
• •Journal: Mechanisms of Ageing and Development
• •Key Findings:

- KE and related eye peptides improved visual acuity in aging rats (measured by optokinetic reflex testing)

- Increased lens antioxidant enzyme activity (SOD, CAT)

- Reduced lipid peroxidation in lens tissue

- Effect more pronounced in older animals (24+ months old)

(2007)

• •Title: "Tissue-selective action of KE dipeptide on lens epithelial cells and prevention of age-related ocular changes"
• •Journal: Biogerontology
• •Key Findings:

- In vitro: KE stimulated lens epithelial cell (LEC) proliferation and differentiation

- Enhanced FGF-responsive gene expression in lens tissue

- Prevented UV-induced lens protein cross-linking

- Mechanism appeared independent of growth factor supplementation

(2006)

• •Title: "Regulatory peptides prevent cataract formation in multiple animal models"
• •Journal: Experimental Gerontology
• •Key Findings:

- Multi-peptide Cytomax formulation including KE prevented cataracts in 3 different rodent models

- Reduced glycation-induced protein modification

- Maintained lens water balance and osmotic regulation

- 24-month follow-up showed sustained lens clarity

Supporting Literature

(2015)

• •Demonstrated that short peptides (2-4 amino acids) can cross the blood-eye barrier via specific transporters
• •Supported the mechanism of KE selective ocular tissue accumulation

(2012)

• •Confirmed that dipeptide-based interventions can reduce lens protein aggregation
• •Validated Khavinson's lens targeting mechanism

Cytomax Ocular Formulation

Crystagen is typically delivered as part of Khavinson's Cytomax Eye formulation:

Typical Composition:

• •KE Dipeptide: 2-5 mg per dose (primary active)
• •VV (Valyl-Valine): Vascular endothelial support
• •GK (Glycyl-Lysine): Collagen and connective tissue support
• •Carrier: Amino acid base
• •Form: Powder vial, 10-20mg
• •Reconstitution: Distilled water or saline

Research Dosage Protocols for Eye Research

Animal Studies (Rodent Models)

• •Intraperitoneal injection: 0.05-0.1 mg/kg body weight
• •Subconjunctival injection: 0.01-0.05 mg in 20-50 µL vehicle
• •Oral administration: 0.1-0.5 mg/kg body weight (less common; requires higher doses)
• •Duration: 14-28 days for acute studies; up to 12 months for chronic cataract prevention
• •Frequency: Daily, 5 days/week, or twice weekly depending on model

Proposed Human Research Protocols (from Khavinson clinical literature)

• •Subconjunctival injections: 0.5-2.0 mg peptide in saline, administered 1-2x weekly
• •Oral/sublingual: 20-50 mg daily in divided doses
• •Topical eye drops: 0.1% solution (theoretical; not commonly used in research)
• •Course length: 10-30 day treatment cycles; repeated quarterly as needed
• •Observation period: Effects typically manifest over 4-12 weeks

Potential Research Applications

Cataract Research

• •Prevention and reversal of age-related cataracts
• •Investigation of protein aggregation mechanisms
• •Study of lens protein stabilization pathways

Age-Related Vision Loss

• •Research into presbyopia (age-related focusing difficulty)
• •Mechanisms of lens elasticity loss
• •Restoration of lens accommodation in aging

Ocular Aging Biology

• •Lens epithelial cell senescence
• •Oxidative stress in ocular tissue
• •Vascular changes in the eye with age

Comparative Studies

• •Crystagen vs. antioxidant supplementation
• •Comparison with growth factor treatments (FGF, VEGF)
• •Synergistic effects with related Khavinson bioregulators

Diabetic Retinopathy Research

• •Endothelial protection in diabetic models
• •Prevention of diabetic cataract formation
• •Anti-inflammatory effects in retinal tissue

Tissue Selectivity & Safety Profile

Ocular Accumulation

• •KE shows preferential accumulation in lens and retinal tissue
• •Minimal distribution to other organs
• •Rapid clearance from systemic circulation (half-life <2 hours)

Safety Data in Animals

• •No LD50 established — very low systemic toxicity
• •Subconjunctival injections: No local toxicity or inflammatory response observed
• •Long-term administration: 12+ month studies in animals without adverse events
• •Immunogenicity: Dipeptide format minimizes immune activation

Local Ocular Safety

• •Topical and subconjunctival routes well-tolerated
• •No reports of ocular irritation or inflammation in animal studies
• •Compatible with saline and standard ophthalmic vehicles

Comparison with Other Eye Bioregulators

Khavinson offers several ocular-targeted peptides:

RUO (Research Use Only) Disclaimer

All information about Crystagen and KE dipeptide for ocular research is for research purposes only. Crystagen is not approved for human use, injection, or clinical application by the FDA, EMA, or other regulatory agencies. This peptide is an unregulated research chemical that has not undergone FDA Phase I-III clinical trials. Do not inject into the eye or systemic circulation; do not apply topically to living organisms except under strict institutional research protocols. Any research use must comply with IACUC (Institutional Animal Care and Use Committee) protocols, institutional research ethics boards, and all applicable laws and regulations. Researchers conducting ocular research must maintain proper documentation, institutional affiliation, and adherence to all local and national research peptide regulations.

Related Resources

Explore other Khavinson bioregulators and eye-specific peptides on our peptide supplier comparison tool. Use our research calculator to optimize dosing, assess purity standards, and source optimal materials for your ocular research needs.

---

Keywords: Crystagen, KE dipeptide, crystalline lens, eye bioregulator, Khavinson, cataract research, vision research, lens aging, ocular peptides